Sairiyo Therapeutics Inc

PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage

PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.

Psyched: MindMed's Nasdaq Debut, PharmaDrug Gets Orphan Drug Designation For DMT, Numinus Launches Clinical Trial Of Naturally Derived Psilocybin

PharmaDrug Inc. (CSE: BUZZ) (Pink: LMLLF) announced an FDA-granted Orphan Drug Designation to its wholly owned subsidiary Sairiyo Therapeutics Inc., for the use of DMT in organ transplantations.